RecruitingPhase 2NCT06295770
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Studying Non-amyloid fibrillary glomerulopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Ladan Zand, MDMayo Clinic
- Intervention
- Obinutuzumab(drug)
- Enrollment
- 20 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Mayo Clinic, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06295770 on ClinicalTrials.gov